Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 1.00 |
| ▸ | PGD | P52209 | 3/20 | 0.53 |
| ▸ | PGK1 | P00558 | 1/20 | 0.47 |
| ▸ | PGK2 | P07205 | 1/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSPO | P30536 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.36 |
| ▸ | SGPL1 | O95470 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18341437 | 1.00 | MPI (1.00) | MPIPGDPGK1PGK2S1PR4 | |
| SCHEMBL2862562 | 1.00 | MPI (1.00) | MPIPGDPGK1PGK2S1PR4 | |
| SCHEMBL20455494 | 1.00 | MPI (1.00) | MPIPGDPGK1PGK2S1PR4 | |
| SCHEMBL891659 | 1.00 | MPI (1.00) | MPIPGDPGK1PGK2S1PR4 | |
| SCHEMBL50110 | 1.00 | MPI (1.00) | MPIPGDPGK1PGK2S1PR4 | |
| Phosphoric Acid SCHEMBL5613914 | 0.98 | MPI (0.96) | MPIPGDPGK1PGK2S1PR4 | |
| Phosphoric Acid SCHEMBL28420442 | 0.98 | MPI (0.96) | MPIPGDPGK1PGK2S1PR4 | |
| SCHEMBL20514347 | 0.92 | MPI (0.85) | MPIPGDPGK1PGK2S1PR4 | |
| SCHEMBL18341440 | 0.92 | MPI (0.85) | MPIPGDPGK1PGK2S1PR4 | |
| SCHEMBL18341412 | 0.91 | MPI (0.82) | MPIPGDPGK1PGK2S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119619354-A | UPLC-MSMS-based method for detecting energy metabolite and application thereof | 江苏三黍生物科技有限公司 | 2025-03-14 | — | — | CN | claimed |
| CN-118360173-A | Method for synthesizing erythrose 4-phosphate precursor and erythritol | 中国科学院微生物研究所 | 2024-07-19 | — | — | CN | claimed |
| CN-117187091-A | Engineering bacterium for producing erythritol and application thereof | 中国科学院微生物研究所 | 2023-12-08 | — | — | CN | claimed |
| CN-111363759-B | Construction method of recombinant yarrowia lipolytica for synthesizing erythritol and bacterial strain thereof | 上海交通大学 | 2022-12-30 | — | — | CN | claimed |
| CN-113388538-A | Recombinant yeast, construction method and application thereof in preparation of tyrosol and derivative | 山东恒鲁生物科技有限公司 | 2021-09-14 | — | — | CN | claimed |
| CN-111139194-B | Recombinant yeast, construction method and application thereof in preparation of tyrosol and derivative | 山东恒鲁生物科技有限公司 | 2021-06-25 | — | — | CN | claimed |
| WO-2020199952-A1 | RECOMBINANT YEAST, CONSTRUCTION METHOD AND APPLICATION THEREOF IN PREPARING TYROSOL AND DERIVATIVES | 烟台华康荣赞生物科技有限公司 | 2020-10-08 | — | — | WO | claimed |
| WO-2020199571-A1 | RECOMBINANT YEAST, CONSTRUCTION METHOD, AND APPLICATION THEREOF IN PREPARING TYROSOL AND DERIVATIVES | 烟台华康荣赞生物科技有限公司 | 2020-10-08 | — | — | WO | claimed |
| CN-111139194-A | Recombinant yeast, construction method and application thereof in preparation of tyrosol and derivative | 烟台华康荣赞生物科技有限公司 | 2020-05-12 | — | — | CN | claimed |
| EP-2021345-A1 | HYDROXYLATED AMIDE SKIN MOISTURIZER | L'Oreal (FR) | 2009-02-11 | — | — | EP | claimed |
| WO-2007137925-A1 | HYDROXYLATED AMIDE SKIN MOISTURIZER | L'OREAL (FR) | 2007-12-06 | — | — | WO | claimed |
| US-20260125713-A1 | PRODUCTION OF MOLECULES BY PERIPLASMIC ENZYMATIC CATALYSIS | BIOC3 (FR) | 2026-05-07 | — | — | US | disclosed |
| US-20260035705-A1 | ENGINEERED MICROORGANISMS WITH G3P ->3PG ENZYME AND/OR FRUCTOSE-1,6-BISPHOSPHATASE INCLUDING THOSE HAVING SYNTHETIC OR ENHANCED METHYLOTROPHY | AGAIN BIO APS (DK) | 2026-02-05 | — | — | US | disclosed |
| WO-2025055194-A1 | GENETICALLY ENGINEERED BACTERIUM FOR DE NOVO SYNTHESIS OF VANILLIN USING GLUCOSE AS SUBSTRATE, AND USE THEREOF | 北京化工大学 | 2025-03-20 | — | — | WO | disclosed |
| EP-4519442-A1 | PRODUCTION OF MOLECULES BY PERIPLASMIC ENZYMATIC CATALYSIS | BIOC3 (FR) | 2025-03-12 | — | — | EP | disclosed |
| US-20100124583-A1 | PROCESSING BIOMASS | XYLECO, INC. (US) | 2010-05-20 | — | — | US | disclosed |
| EP-2021345-A1 | HYDROXYLATED AMIDE SKIN MOISTURIZER | L'Oreal (FR) | 2009-02-11 | — | — | EP | disclosed |
| CN-101300344-A | Modified transketolase and use thereof | DSM IP ASSETS BV (NL) | 2008-11-05 | — | — | CN | disclosed |
| WO-2007137925-A1 | HYDROXYLATED AMIDE SKIN MOISTURIZER | L'OREAL (FR) | 2007-12-06 | — | — | WO | disclosed |
| CN-1371417-A | Corynebacterium glutamicum genes encoding metabolic pathway proteins | BASF AG (DE) | 2002-09-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035705-A1 | ENGINEERED MICROORGANISMS WITH G3P ->3PG ENZYME AND/OR FRUCTOSE-1,6-BISPHOSPHATASE INCLUDING THOSE HAVING SYNTHETIC OR ENHANCED METHYLOTROPHY | ME1, FBP1, ME3 | MPI 38/4885PGD 10/4885PGK1 44/4885 |
| US-20260125713-A1 | PRODUCTION OF MOLECULES BY PERIPLASMIC ENZYMATIC CATALYSIS | MGAM, MRPL21, NOTUM | MPI 469/4885PGD 106/4885PGK1 627/4885 |
| US-20100124583-A1 | PROCESSING BIOMASS | FIP1L1, MANBA, BCAT2 | MPI 122/4885PGD 59/4885PGK1 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.